Plerixafor

FDA Approved: * July 24, 2023
Pharm Company: * DR REDDYS LABS LTD
Category: Cancer

Plerixafor (INN and USAN, trade name Mozobil) is an immunostimulant used to mobilize hematopoietic stem cells in cancer patients into the bloodstream. The stem cells are then extracted from the blood and transplanted back to the patient. The drug was developed by AnorMED, which was subsequently bought by Genzyme. Contents 1 Medical uses 2 Contraindications 2.1 Pregnancy and lactation 3 Adverse effects 4 Interactions 5 Pharmacology 5.1 Mechanism of action 5.2 Pharmacokinetics 6 Chemist... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Plerixafor 24 mg/1.2ml Subcutaneous Injection, Solution
NDC: 0480-4320
Labeler:
Teva Pharmaceuticals, Inc.
Plerixafor 20 mg/ml Subcutaneous Injection, Solution
NDC: 25021-416
Labeler:
Sagent Pharmaceuticals
Plerixafor 24 mg/1.2ml Subcutaneous Solution
NDC: 43598-308
Labeler:
Dr. Reddy's Laboratories Inc
Plerixafor 24 mg/1.2ml Subcutaneous Solution
NDC: 55150-356
Labeler:
Eugia Us LLC
Plerixafor 24 mg/1.2ml Subcutaneous Injection, Solution
NDC: 65219-284
Labeler:
Fresenius Kabi USA, LLC
Plerixafor 24 mg/1.2ml Subcutaneous Injection, Solution
NDC: 68083-155
Labeler:
Gland Pharma Limited
Plerixafor 24 mg/1.2ml Subcutaneous Injection, Solution
NDC: 70121-1694
Labeler:
Amneal Pharmaceuticals LLC
Plerixafor 24 mg/1.2ml Subcutaneous Injection
NDC: 70710-1208
Labeler:
Zydus Pharmaceuticals USA Inc.
Plerixafor 24 mg/1.2ml Subcutaneous Injection
NDC: 70771-1776
Labeler:
Zydus Lifesciences Limited
Plerixafor 24 mg/1.2ml Subcutaneous Solution
NDC: 71288-155
Labeler:
Meitheal Pharmaceuticals Inc.
More Results

Related Brands

Drugs with the same active ingredients